Early this year, Jonathan Got wrote a piece about the proposed Canada Pension Plan (CPP) money-back guarantee — a death benefit concept developed by Dr. Bonnie-Jeanne MacDonald designed to encourage ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The final monthly Canada Pension Plan and Old Age Security payments for 2025 are set to hit bank accounts Monday. Anyone 60 years of age or older is entitled for the Canada Pension Plan (CPP) — a ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Abstract: In response to the susceptibility of networked systems to factors such as inaccurate modeling and sensor failures, a robust state estimation method for uncertain linear discrete systems with ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

I'll be brief. I need to be able to get 1 item from 2 sets of items and drop them together. Let's say there are 3 items in each set and we need to ensure that 1 item drops from the first set and 1 ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...